
Biomarkers
Description
Global Biomarkers Market to Reach US$235.2 Billion by 2030
The global market for Biomarkers estimated at US$108.7 Billion in the year 2024, is expected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.7% over the analysis period 2024-2030. Safety, one of the segments analyzed in the report, is expected to record a 13.9% CAGR and reach US$89.8 Billion by the end of the analysis period. Growth in the Efficacy segment is estimated at 12.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$27.7 Billion While China is Forecast to Grow at 17.8% CAGR
The Biomarkers market in the U.S. is estimated at US$27.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$57.8 Billion by the year 2030 trailing a CAGR of 17.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.4% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.
Biomarkers - Key Trends and Drivers Summarized
Biomarkers have revolutionized healthcare by providing precise tools for disease identification and management, enhancing treatment efficacy, and fostering the development of new drugs. These biological indicators are measurable signals of various biological states or conditions, crucial for diagnosing diseases and monitoring the effectiveness of treatments. Initially, disease detection relied heavily on observable physical symptoms and sample analysis. However, with significant technological advancements over the years, the discovery and development of numerous biomarkers have greatly enriched medical diagnostics and treatment options. This evolution has facilitated earlier and more precise diagnoses, improved treatment strategies, and minimized errors, leading to better and more cost-effective healthcare solutions.
The integration of biomarkers into modern medicine spans various functions, from diagnosing conditions to predicting treatment outcomes. They are classified into categories such as molecular, radiographic, histologic, and physiologic biomarkers, each serving unique roles. For example, molecular biomarkers are found in biological samples like blood and cerebrospinal fluid, indicating molecular interactions and biochemical changes. Radiographic biomarkers, derived from imaging studies, non-invasively assess health conditions, such as bone density. Histologic biomarkers reflect biochemical changes in tissues or cells, crucial for diagnosing and staging cancers. Physiologic biomarkers, like blood pressure or heart rate, provide direct insights into bodily functions. These biomarkers enhance disease management through various stages of healthcare, including diagnostic, prognostic, predictive, and monitoring biomarkers, thereby optimizing patient care and treatment strategies.
The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.
SCOPE OF STUDY:The report analyzes the Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Safety, Efficacy, Validation); Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Diseases); Application (Drug Discovery & Development, Diagnostics, Personalized Medicines, Other Applications)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 282 Featured) -
- Abbott Molecular, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- QIAGEN NV
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Biomarkers – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- Global Economic Update
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Growth of Biomarker-Based Diagnostics and Companion Diagnostics
- Advancements in Genomics and Proteomics Technologies
- Rising Adoption of Biomarkers in Drug Development and Clinical Trials
- Impact of COVID-19 Pandemic on Biomarker Research and Development
- Government Regulations and Standards for Biomarker Validation and Approval
- Expansion of Biomarker Applications in Oncology and Chronic Diseases
- Development of Liquid Biopsy and Non-Invasive Biomarker Technologies
- Consumer Preferences for Early Detection and Preventive Healthcare
- Role of Biomarkers in Enhancing Clinical Decision-Making
- Market Penetration of Digital Health and Biomarker Integration
- Influence of Artificial Intelligence and Machine Learning on Biomarker Discovery
- Growth of Biomarker-Based Research in Neurological Disorders
- Challenges Related to Biomarker Validation and Clinical Utility
- Emerging Markets and Growth Opportunities in Developing Regions
- Future Trends and Innovations in Biomarker Technologies and Applications
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 8: World Historic Review for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 9: World 15-Year Perspective for Efficacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 11: World Historic Review for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 12: World 15-Year Perspective for Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 18: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 20: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 21: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 23: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 24: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 26: World Historic Review for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 27: World 15-Year Perspective for Immunological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 28: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 29: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 30: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 31: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 32: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 33: World 15-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 34: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 35: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 36: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 37: World Recent Past, Current & Future Analysis for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 38: World Historic Review for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 39: World 15-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 40: World Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- CANADA
- TABLE 50: Canada Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 53: Canada Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- JAPAN
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 59: Japan Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 62: Japan Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- CHINA
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 68: China Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 71: China Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: China Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: China 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- EUROPE
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 77: Europe Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- FRANCE
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 89: France Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 92: France Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: France Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: France 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- GERMANY
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 98: Germany Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 101: Germany Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- ITALY
- TABLE 107: Italy Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 110: Italy Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 116: UK Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 119: UK Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: UK 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 125: Spain Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Spain Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Spain 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 128: Spain Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Spain 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 134: Russia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Russia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Russia 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 137: Russia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Russia 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of Europe 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Rest of Europe 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 153: Asia-Pacific Historic Review for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Asia-Pacific 15-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Asia-Pacific 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- AUSTRALIA
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 164: Australia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Australia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Australia 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 167: Australia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Australia 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- INDIA
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 173: India Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: India Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: India 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 176: India Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: India Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: India 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 182: South Korea Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: South Korea Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: South Korea 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: South Korea 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 200: Latin America Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 201: Latin America Historic Review for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Latin America 15-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Latin America 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 212: Argentina Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Argentina Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Argentina 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Argentina 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 221: Brazil Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Brazil Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Brazil 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Brazil 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 230: Mexico Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Mexico Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Mexico 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Mexico 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Latin America 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Latin America 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 248: Middle East Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 249: Middle East Historic Review for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Middle East 15-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Middle East 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- IRAN
- TABLE 260: Iran Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Iran Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Iran 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 263: Iran Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: Iran 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 269: Israel Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: Israel Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: Israel 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 272: Israel Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: Israel 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: Saudi Arabia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: Saudi Arabia 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: Saudi Arabia 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 287: UAE Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: UAE Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: UAE 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 290: UAE Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: UAE 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Middle East 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Middle East 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- AFRICA
- Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 305: Africa Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 306: Africa Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 307: Africa 15-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2015, 2025 & 2030
- TABLE 308: Africa Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2015, 2025 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 313: Africa 15-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates